Peregrine Asset Advisers’s GoodRx Holdings GDRX Stock Holding History

Peregrine Asset Advisers’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-23,052	Closed	-$930K	–	130
2020 Q4	$930K	Buy	+23,052	New	+$1.06M	0.43%	55

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Peregrine Asset Advisers's GDRX Position: Q1 2021 in Review

Peregrine Asset Advisers sold out of GoodRx Holdings (GDRX) in Q1 2021, closing a stake of 23,052 shares — an estimated $930K sold.

Peregrine Asset Advisers first reported a position in GDRX in Q4 2020 and held it in 1 quarter. The position peaked at $930K in Q4 2020. 205 funds tracked by Wall St. Rank hold GDRX as of Q1 2021.

Peregrine Asset Advisers reported no remaining GoodRx Holdings position as of Q1 2021 after selling out during the quarter.
Peregrine Asset Advisers sold 23,052 GoodRx Holdings shares in Q1 2021, an estimated $930K.
Peregrine Asset Advisers first reported a position in GoodRx Holdings in Q4 2020 and held it in 1 quarter.
Peregrine Asset Advisers's GoodRx Holdings position peaked at $930K in Q4 2020.
205 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2021.

Based on Peregrine Asset Advisers's 13F filing for Q1 2021, filed 13 May 2021.